Multiple endocrine neoplasia type 1 future or investigational therapies

Revision as of 15:44, 21 July 2016 by Irfan Dotani (talk | contribs)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 future or investigational therapies

CDC on Multiple endocrine neoplasia type 1 future or investigational therapies

Multiple endocrine neoplasia type 1 future or investigational therapies in the news

Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.

Future or Investigational Therapies

  • Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
  • National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
  • Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
  • mTOR inhibitors for pancreatic neuroendocrine tumors are other subjects undergoing investigation.
  • Role of surgery for non functioning pancreatic neuroendocrine tumors is also under investigation.
  • The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1
  • Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
  • Molecular phenotyping of tumors have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.

References

  1. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check |pmid= value (help).

Template:WS Template:WH